Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesEndocrinologyHealth Net Abaloparatide (Tymlos) Coverage Update …
    Ask Trek AI about this page
    ModifiedHealth NetPolicy N/A

    Clinical Policy: Abaloparatide (Tymlos)

    Customize your policy alerts

    Sign up for all Health Net policy alerts

    Know when Health Net releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing medical necessity, prior authorization, and coverage criteria for abaloparatide (Tymlos) for treatment of postmenopausal and male osteoporosis for Health Net lines of business (Commercial, HIM, Medicaid). Applies to providers requesting coverage under the plan.

    Policy Summary
    PayerHealth Net
    PolicyAbaloparatide (Tymlos) — coverage criteria for postmenopausal and male osteoporosis
    Policy CodePolicy N/A
    Change TypeIndication expansionapproval duration revisionstep therapy clarifications
    Effective Date07.17
    Next Review Date
    Key ActionSubmit prior authorization with supporting clinical documentation demonstrating diagnosis, prior bisphosphonate history or applicable exception, and dosing within limits.
    SourceLink
    POLICY UPDATE CHANGES

    Added newly approved indication of male osteoporosis to criteria.

    Revised initial approval duration to 12 months for Medicaid/HIM and added Commercial approval duration of 6 months or to the member's renewal date, whichever is longer.

    Clarified failure of generic alendronate is preferred and clarified dosage regimen.

    Added option to bypass bisphosphonate trial if member has experienced loss of BMD, lack of BMD increase, or had an osteoporotic/fragility fracture while on bisphosphonate therapy.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    80 mcg/daymax daily dose
    2 yearslifetime limit
    1 pen/30ddispensing limit
    6 monthsapproval (Commercial)
    12 monthsapproval (Medicaid/HIM)
    male osteoporosisnew indication

    Coverage Criteria for Abaloparatide (Tymlos)

    Initial Therapy

    Covered when ALL of the following are met for diagnosis of postmenopausal osteoporosis (PMO) or male osteoporosis:

    Diagnosis and age: Diagnosis of postmenopausal osteoporosis (PMO) or male osteoporosis

    Age ≥ 18 years or documentation of closed epiphyses on X‑ray

    Evidence of very high fracture risk: Member is at very high risk for fracture as evidenced by ONE of: recent osteoporotic fracture within the past 12 months; BMD T‑score at hip or spine ≤ -3.0; or BMD T‑score ≤ -2.5 plus a major osteoporotic fracture (spine, forearm, wrist, humerus).

    See Appendix E for T‑score definitions

    Prior bisphosphonate pathway or exceptions: Member has completed a 3‑year trial of bisphosphonate therapy (generic alendronate preferred) at up to maximally indicated doses OR meets one of the exceptions: all bisphosphonates contraindicated; clinically significant adverse effects to both IV and PO formulations; loss of BMD while on bisphosphonate therapy; osteoporotic/fragility fracture while on bisphosphonate therapy; lack of BMD increase after ≥12 months of bisphosphonate therapy.3 years

    Appendix B and D provide details on alternatives and contraindications; option to bypass trial added in 1Q 2022 updates

    Dose and cumulative exposure limits: Requested dose does not exceed 80 mcg per day; dispensing does not exceed 1 pen every 30 days; member has not received ≥ 2 years cumulative abaloparatide therapy.80 mcg/day; 2 years cumulative

    Dose and duration per Dosage and Administration

    Continuation Therapy

    Continued therapy is covered when the member meets ONE of the following:

    Continuation eligibility: Member is currently receiving medication via the Centene benefit and is responding positively to therapy; OR member previously met initial approval criteria; OR member is in continuity of care regulations for state/product.

    Member must not have exceeded 2 years cumulative abaloparatide therapy and dose limits remain as specified; dose increases must not exceed 80 mcg/day and 1 pen every 30 days.

    Policy updates and coverage-modifying criteria

    Policy-level coverage stance and notable criteria updates

    Indication expansion: Policy criteria were updated to include male osteoporosis as an approved indication for abaloparatide.

    1Q 2023 annual review

    Bypass of bisphosphonate trial: Bypass of prior bisphosphonate trial allowed if member has experienced loss of BMD, lack of BMD increase, or an osteoporotic/fragility fracture while on bisphosphonate therapy (in addition to contraindications or adverse effects).

    Added in 1Q 2022 update

    Approval durations and updates: Initial and continuation approval durations differ by line of business: Medicaid/HIM initial approval revised to 12 months; Commercial continuation approval modified to 6 months or to the member's renewal date, whichever is longer. Policy clarifications include preferred failure of generic alendronate and added Appendix E for T‑score interpretation.

    1Q 2024 and 1Q 2025 updates

    Non‑FDA approved indications that are not specifically addressed in this policy are not authorized for coverage unless the request includes sufficient documentation of efficacy and safety consistent with the applicable off‑label use policies: CP.CPA.09 for Commercial, HIM.PA.154 for Health Insurance Marketplace, or CP.PMN.53 for Medicaid, or other evidence of coverage documentation.

    During the 1Q 2022 annual review the policy documentation was updated to note that the osteosarcoma black box warning was removed from Appendix C; no explicit exclusion for osteosarcoma is stated in the excerpt provided.

    Use of abaloparatide (or other agents) for non‑FDA approved indications without sufficient documentation of efficacy and safety consistent with the plan’s off‑label use policies is considered not authorized and may be denied.

    Within the excerpted content there are no explicit entries listing conditions that are determined to be "not medically necessary." Requests may still be denied for lack of supporting documentation or failure to meet the stated coverage criteria.

    Coding, Dose Limits, and Approval Durations

    Referenced HCPCS CodesHCPCS
    J3490Unclassified drugs
    BMD T-score thresholds
    Osteoporosis definitionOsteoporosis is defined as a BMD T-score ≤ -2.5 (AACE/WHO guidance).
    Very high fracture risk - T-scoreBMD T-score at the hip or spine ≤ -3.0 qualifies as very high risk.
    T-score plus fractureBMD T-score ≤ -2.5 plus a major osteoporotic fracture (spine, forearm, wrist, humerus) qualifies.
    Dose limit
    Maximum single‑day dose80 mcg subcutaneously once daily.
    Dosing routeSubcutaneous (SC) administration.
    Dosing frequency

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for this therapy. Approval durations vary by line of business: Medicaid/HIM — 12 months; Commercial — 6 months or to the member's renewal date, whichever is longer. Inclusion or exclusion of codes in this clinical policy does not guarantee coverage; providers should reference the most up-to-date professional coding guidance when submitting claims for reimbursement.

    • Approval duration: Medicaid/HIM = 12 months; Commercial = 6 months or to member's renewal date, whichever is longer
    • Coding inclusion disclaimer: Codes shown are informational only and do not ensure coverage; verify current coding guidance prior to claim submission
    Documentation Required

    Required Supporting Documentation

    Provider must submit supporting clinical documentation to demonstrate that the member meets all approval criteria. Acceptable documentation includes office chart notes, relevant laboratory results, bone mineral density (BMD) reports (including T-scores), imaging reports documenting fractures, and prior therapy records documenting bisphosphonate use, adverse effects, or contraindications.

    Background on Abaloparatide

    Abaloparatide (Tymlos) is a parathyroid hormone‑related peptide analog indicated for the treatment of osteoporosis in postmenopausal women and in men who are at high risk for fracture or who have failed or are intolerant to other therapies. The agent increases bone mineral density and has been shown to reduce vertebral and non‑vertebral fracture risk in postmenopausal women; high fracture risk is defined by history of osteoporotic fracture or multiple risk factors with BMD thresholds per guideline definitions.

    Definitions and Risk Criteria

    High risk of fracture definition
    High risk of fracture - clinical definitionHistory of an osteoporotic fracture or multiple risk factors for fracture defines high risk.
    Use of BMD T‑score per guidelinesAACE/WHO guidance uses BMD T‑score; osteoporosis is T‑score ≤ -2.5.
    Very high risk criteriaVery high risk includes recent osteoporotic fracture within 12 months, BMD T‑score ≤ -3.0, or T‑score ≤ -2.5 with a major osteoporotic fracture.
    Bypass of bisphosphonate trial
    Bisphosphonate trial bypass - allowanceBypass of a bisphosphonate trial is allowed if the member experienced loss of BMD, lack of BMD increase after ≥12 months, or sustained an osteoporotic/fragility fracture while on bisphosphonate therapy.
    Standard bisphosphonate requirement
    Policy Summary
    PayerHealth Net
    PolicyAbaloparatide (Tymlos) — coverage criteria for postmenopausal and male osteoporosis
    Policy CodePolicy N/A
    Change TypeIndication expansionapproval duration revisionstep therapy clarifications
    Effective Date07.17
    Next Review Date
    Key ActionSubmit prior authorization with supporting clinical documentation demonstrating diagnosis, prior bisphosphonate history or applicable exception, and dosing within limits.
    SourceLink
    On This Page
    Coverage Criteria for Abaloparatide (Tymlos)Coding, Dose Limits, and Approval DurationsProvider Actions, Prior Authorization, and DocumentationBackground on AbaloparatideDefinitions and Risk Criteria
    Once daily (QD).
    Cumulative PTH analog exposure
    Lifetime cumulative PTH analog exposureUp to 2 years cumulative abaloparatide (PTH analog) lifetime.
    Policy clarificationUse is limited to < 2 years cumulative abaloparatide therapy as noted in 1Q 2022 updates.
    Dose relationshipCumulative exposure counted toward the 2‑year limit includes prior abaloparatide therapy; Forteo distinctions noted in update.
    Approval duration (Commercial)
    Commercial approval duration6 months or to the member's renewal date, whichever is longer.
    Context of changeModified for Commercial continuation of therapy in 1Q 2025 annual review.
    Typical dispensing intervalDispensing limits referenced as 1 pen every 30 days in dosage guidance.
    Approval duration (Medicaid/HIM)
    Medicaid/HIM approval duration12 months.
    Policy revisionInitial approval duration revised to 12 months for Medicaid/HIM (noted in 1Q 2025 annual review).
    Reference noteSee Coding Implications entries describing the 1Q 2025 revisions.
    • Office chart notes documenting diagnosis and clinical rationale
    • BMD reports showing T-scores and dates of testing (see Appendix E for T-score interpretation)
    • Documentation of prior bisphosphonate therapy: dates, agent (generic alendronate preferred), dose, duration (3 years preferred), and reason for discontinuation if applicable
    • Records of fractures or imaging confirming recent osteoporotic/fragility fractures
    • Laboratory results or other tests supporting contraindications or adverse events
    Documentation Required

    Required Clinical Context

    Clinical context that affects authorization decisions includes documented classification of 'very high risk' for fracture per updated guideline definitions, evidence of prior bisphosphonate therapy (including whether failure, intolerance, or contraindication exists), and documentation of any BMD loss or lack of BMD increase while on therapy. Requests for non‑FDA indications require sufficient off‑label justification per applicable off‑label use policies.

    • Very high risk for fracture definitions updated per 2020 guideline revisions (see policy references and Appendix E)
    • If requesting coverage based on prior bisphosphonate trial bypass, provide objective evidence (loss of BMD, lack of BMD increase after ≥12 months, or fracture while on therapy)
    • Non‑FDA indications require documentation per off‑label use policies (CP.CPA.09 for commercial; HIM.PA.154 for marketplace; CP.PMN.53 for Medicaid)
    Step Therapy

    Bisphosphonate Trial Preference and Bypass

    Step-therapy preference: a trial and failure of a generic alendronate (bisphosphonate) is generally preferred prior to coverage. Bypass of the bisphosphonate trial is allowed when there is documentation of contraindication, clinically significant adverse effects to both oral and IV bisphosphonates, loss of BMD while on bisphosphonate therapy, lack of BMD increase after ≥12 months of therapy, or occurrence of an osteoporotic/fragility fracture while receiving bisphosphonate therapy.

    • Preferred step: failure of generic alendronate prior to approval (unless contraindicated or bypass criteria met)
    • Bypass criteria: contraindication to all bisphosphonates; significant adverse effects to both IV and PO formulations; documented loss of BMD on therapy; lack of BMD increase after ≥12 months; fracture while on bisphosphonate therapy
    • Document bisphosphonate trial details: agent, dose, duration (3 years preferred), and reason for discontinuation
    Members generally must complete a 3‑year trial of bisphosphonate therapy (generic alendronate preferred) unless contraindicated or exceptions apply.
    Policy historyOption to bypass was added in the 1Q 2022 update to criteria.